Organon & Co. (NYSE:OGN) Sets New 12-Month High - Time to Buy?

Key Points

• Sun Pharma agreed to acquire Organon for $14.00 per share in an $11.75 billion all‑cash deal, fueling a surge to a new 52‑week high and massive single‑day trading volume and options activity as arbitrage/speculative interest picked up.
• Several shareholder law firms have opened investigations into whether Organon’s board obtained a fair price or breached fiduciary duties, creating legal and closing‑risk that could delay or alter the deal terms.
• Despite the takeover premium, Wall Street consensus remains negative (consensus rating "Reduce", target ~$8.50) and Organon recently missed EPS and revenue expectations and carries high leverage, raising questions about underlying fundamentals beyond the bid.

Shares of Organon & Co. (NYSE:OGN - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $13.24 and last traded at $13.1550, with a volume of 133808830 shares trading hands. The stock had previously closed at $11.26.

Key Headlines Impacting Organon & Co.

Here are the key news stories impacting Organon & Co. this week:

• Positive Sentiment: Sun Pharma agreed to buy Organon for $14.00 per share in an $11.75B all‑cash deal — the primary driver of the rally as investors value the takeover premium and likely cash consideration. Sun Pharma to acquire Organon
• Positive Sentiment: Market commentary highlights strategic rationale (women’s‑health franchise, biosimilars, global footprint) and notes the large premium — supportive for near‑term share prices and takeover arbitrage trades. Organon Stock Soars After Sun Seals Takeover
• Positive Sentiment: Unusual options activity and massive single‑day trading volume show speculative and arbitrage interest (call buying increased and volume far above average), reinforcing upward price momentum. (Trade data entry)
• Neutral Sentiment: Analyst and press pieces explore whether Sun’s bid reflects value for a company with slower growth and meaningful debt — useful context for whether the offer could be re‑priced or attract competing bids. Why is Sun Pharma betting $11.75B on a struggling US drugmaker?
• Negative Sentiment: Several shareholder law firms have opened investigations into whether Organon’s board obtained a fair price or breached fiduciary duties — a source of legal risk that can delay closing, increase costs, or trigger renegotiation/claims. Johnson Fistel Investigates
• Negative Sentiment: Additional law firms (Halper Sadeh, Monteverde & Associates, Ademi LLP) have issued shareholder alerts and probes, increasing the likelihood of litigation or contested fairness claims. Halper Sadeh LLC Investigates Monteverde & Associates Alert Ademi LLP Alert

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on OGN shares. Zacks Research upgraded shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 14th. Wall Street Zen cut shares of Organon & Co. from a "buy" rating to a "hold" rating in a research report on Saturday, January 31st. Finally, Barclays boosted their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and four have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and a consensus target price of $8.50.

Organon & Co. Stock Up 16.8%

The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23. The stock has a market capitalization of $3.42 billion, a PE ratio of 18.53, a PEG ratio of 1.04 and a beta of 0.67. The company has a 50 day moving average price of $7.33 and a 200-day moving average price of $7.66.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The business had revenue of $1.51 billion for the quarter, compared to analysts' expectations of $1.52 billion. During the same period last year, the firm posted $0.90 earnings per share. Organon & Co.'s quarterly revenue was down 5.3% on a year-over-year basis. As a group, analysts forecast that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Monday, February 23rd were given a dividend of $0.02 per share. The ex-dividend date was Monday, February 23rd. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.'s payout ratio is currently 11.27%.

Hedge Funds Weigh In On Organon & Co.

Several hedge funds and other institutional investors have recently modified their holdings of OGN. Foster Dykema Cabot & Partners LLC purchased a new position in shares of Organon & Co. during the third quarter valued at about $29,000. Farther Finance Advisors LLC raised its holdings in Organon & Co. by 87.8% in the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company's stock worth $31,000 after purchasing an additional 2,033 shares in the last quarter. Rothschild Investment LLC raised its holdings in Organon & Co. by 73.1% in the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company's stock worth $42,000 after purchasing an additional 1,646 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new position in Organon & Co. in the fourth quarter worth $44,000. Finally, Kestra Advisory Services LLC bought a new position in Organon & Co. in the fourth quarter worth $47,000. Hedge funds and other institutional investors own 77.43% of the company's stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.